NASDAQ:CDXS Codexis (CDXS) Stock Price, News & Analysis $3.14 -0.07 (-2.18%) (As of 10/31/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Codexis Stock (NASDAQ:CDXS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Codexis alerts:Sign Up Key Stats Today's Range$3.08▼$3.2650-Day Range$2.62▼$3.5252-Week Range$1.51▼$4.91Volume468,166 shsAverage Volume524,377 shsMarket Capitalization$222.71 millionP/E RatioN/ADividend YieldN/APrice Target$8.75Consensus RatingModerate Buy Company OverviewCodexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.Read More… The real reason Elon is fully endorsing Trump (Ad)Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. Watch this new documentary and you’ll discover what Elon knows, Codexis Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks87th Percentile Overall ScoreCDXS MarketRank™: Codexis scored higher than 87% of companies evaluated by MarketBeat, and ranked 165th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingCodexis has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCodexis has only been the subject of 2 research reports in the past 90 days.Read more about Codexis' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Codexis are expected to decrease in the coming year, from ($0.75) to ($0.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Codexis is -2.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Codexis is -2.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCodexis has a P/B Ratio of 2.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Codexis' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.82% of the outstanding shares of Codexis have been sold short.Short Interest Ratio / Days to CoverCodexis has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Codexis has recently decreased by 11.50%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCodexis does not currently pay a dividend.Dividend GrowthCodexis does not have a long track record of dividend growth. Sustainability and ESG2.5 / 5Environmental Score-3.67 Percentage of Shares Shorted2.82% of the outstanding shares of Codexis have been sold short.Short Interest Ratio / Days to CoverCodexis has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Codexis has recently decreased by 11.50%, indicating that investor sentiment is improving significantly. News and Social Media2.7 / 5News Sentiment0.80 News SentimentCodexis has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Codexis this week, compared to 2 articles on an average week. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Codexis insiders have bought more of their company's stock than they have sold. Specifically, they have bought $3,514,910.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.10% of the stock of Codexis is held by insiders.Percentage Held by Institutions78.54% of the stock of Codexis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Codexis' insider trading history. Receive CDXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Codexis and its competitors with MarketBeat's FREE daily newsletter. Email Address CDXS Stock News HeadlinesCodexis Reports Third Quarter 2024 Financial ResultsOctober 31 at 4:29 PM | markets.businessinsider.comCodexis Announces Three siRNA Manufacturing Data Presentations at TIDES Europe Annual MeetingOctober 24, 2024 | globenewswire.comUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip?October 31, 2024 | Behind the Markets (Ad)Codexis (CDXS) to Release Quarterly Earnings on ThursdayOctober 24, 2024 | americanbankingnews.comCodexis announces employment inducement grantsOctober 15, 2024 | finance.yahoo.comCodexis Announces New Employment Inducement GrantsOctober 14, 2024 | globenewswire.comCodexis to Report Third Quarter 2024 Financial Results on October 31October 10, 2024 | globenewswire.comCodexis Inc (CDXS) Q2 2024 Earnings Call Highlights: Navigating Revenue Challenges and ...October 9, 2024 | gurufocus.comSee More Headlines CDXS Stock Analysis - Frequently Asked Questions How have CDXS shares performed this year? Codexis' stock was trading at $3.05 at the beginning of the year. Since then, CDXS stock has increased by 3.0% and is now trading at $3.14. View the best growth stocks for 2024 here. How were Codexis' earnings last quarter? Codexis, Inc. (NASDAQ:CDXS) posted its quarterly earnings data on Thursday, August, 8th. The biotechnology company reported ($0.32) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by $0.06. The biotechnology company had revenue of $7.98 million for the quarter, compared to analysts' expectations of $7.64 million. Codexis had a negative trailing twelve-month return on equity of 64.06% and a negative net margin of 125.41%. Who are Codexis' major shareholders? Top institutional shareholders of Codexis include Assenagon Asset Management S.A. (1.56%), abrdn plc (1.13%), Private Advisor Group LLC (0.39%) and Perkins Capital Management Inc. (0.23%). Insiders that own company stock include Opaleye Management Inc, John J Nicols, Byron L Dorgan, Sriram Ryali, Kevin Norrett, Margaret Nell Fitzgerald, Dennis P Wolf and Patrick Y Yang. View institutional ownership trends. How do I buy shares of Codexis? Shares of CDXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Codexis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Codexis investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), Walt Disney (DIS) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings8/08/2024Today10/31/2024Next Earnings (Confirmed)10/31/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Industrial organic chemicals Sub-IndustryBiotechnology Current SymbolNASDAQ:CDXS CUSIP19200510 CIK1200375 Webwww.codexis.com Phone(650) 421-8100Fax650-421-8102Employees250Year FoundedN/APrice Target and Rating Average Stock Price Target$8.75 High Stock Price Target$11.00 Low Stock Price Target$5.00 Potential Upside/Downside+178.7%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-76,240,000.00 Net Margins-125.41% Pretax Margin-125.30% Return on Equity-64.06% Return on Assets-35.67% Debt Debt-to-Equity Ratio0.46 Current Ratio2.99 Quick Ratio2.92 Sales & Book Value Annual Sales$60.89 million Price / Sales3.66 Cash FlowN/A Price / Cash FlowN/A Book Value$1.24 per share Price / Book2.53Miscellaneous Outstanding Shares70,927,000Free Float69,438,000Market Cap$222.71 million OptionableOptionable Beta2.08 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report This page (NASDAQ:CDXS) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Codexis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Codexis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.